Deep Learning Algorithms Achieved Satisfactory Predictions When Trained on a Novel Collection of Anticoronavirus Molecules

Harigua-Souiai, Emna and Heinhane, Mohamed Mahmoud and Abdelkrim, Yosser Zina and Souiai, Oussama and Abdeljaoued-Tej, Ines and Guizani, Ikram (2021) Deep Learning Algorithms Achieved Satisfactory Predictions When Trained on a Novel Collection of Anticoronavirus Molecules. Frontiers in Genetics, 12. ISSN 1664-8021

[thumbnail of pubmed-zip/versions/1/package-entries/fgene-12-744170/fgene-12-744170.pdf] Text
pubmed-zip/versions/1/package-entries/fgene-12-744170/fgene-12-744170.pdf - Published Version

Download (1MB)

Abstract

Drug discovery and repurposing against COVID-19 is a highly relevant topic with huge efforts dedicated to delivering novel therapeutics targeting SARS-CoV-2. In this context, computer-aided drug discovery is of interest in orienting the early high throughput screenings and in optimizing the hit identification rate. We herein propose a pipeline for Ligand-Based Drug Discovery (LBDD) against SARS-CoV-2. Through an extensive search of the literature and multiple steps of filtering, we integrated information on 2,610 molecules having a validated effect against SARS-CoV and/or SARS-CoV-2. The chemical structures of these molecules were encoded through multiple systems to be readily useful as input to conventional machine learning (ML) algorithms or deep learning (DL) architectures. We assessed the performances of seven ML algorithms and four DL algorithms in achieving molecule classification into two classes: active and inactive. The Random Forests (RF), Graph Convolutional Network (GCN), and Directed Acyclic Graph (DAG) models achieved the best performances. These models were further optimized through hyperparameter tuning and achieved ROC-AUC scores through cross-validation of 85, 83, and 79% for RF, GCN, and DAG models, respectively. An external validation step on the FDA-approved drugs collection revealed a superior potential of DL algorithms to achieve drug repurposing against SARS-CoV-2 based on the dataset herein presented. Namely, GCN and DAG achieved more than 50% of the true positive rate assessed on the confirmed hits of a PubChem bioassay.

Item Type: Article
Subjects: STM Digital Press > Medical Science
Depositing User: Unnamed user with email support@stmdigipress.com
Date Deposited: 17 Jan 2023 11:51
Last Modified: 17 Jun 2024 06:59
URI: http://publications.articalerewriter.com/id/eprint/66

Actions (login required)

View Item
View Item